Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An Application in a clinical trial of unresectable non-small-cell lung cancer

Takuhiro Yamaguchi, Yasuo Ohashi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The CPT-11 trial was conducted to confirm the superiority of CDDP+CPT-11 (CPT-P) arm to CDDP+VDS (VDS-P) arm with regard to survival for patients with previously untreated advanced (stage IIIB/IV) non-small-cell lung cancer. However, the CPT-P arm did not show the survival benefit for patients with stage IIIB. The proportion of patients with stage IIIB treated by active radiation given as second-line treatment (second-line radiotherapy) after initial (first-line) treatment was 45 per cent in the CPT-P arm while 61 per cent in the VDS-P arm. This showed that not proving survival advantage in the CPT-P arm might be due to the benefits of second-line radiotherapy. We apply two causal models appeared in the companion paper to test and estimate the survival differences that would have been observed if all the patients had been received the same second-line radiotherapy. Based on several assumptions, we inferred that the CPT-P arm still would not have showed survival advantage if all the patients had been given identical second-line radiotherapy.

Original languageEnglish
Pages (from-to)2005-2022
Number of pages18
JournalStatistics in Medicine
Volume23
Issue number13
DOIs
Publication statusPublished - 2004 Jul 15
Externally publishedYes

Keywords

  • Cancer clinical trials
  • Causal inference
  • Direct effect
  • ITT analysis
  • Post-randomization variables
  • Second-line treatment

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability

Fingerprint Dive into the research topics of 'Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An Application in a clinical trial of unresectable non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this